How willing are you to pay approximately $1,000 each month to lose weight? To many across the globe, it’s an option worth taking. In fact, with global obesity rates spiking higher than ever, more patients are relying on them to manage their weight, treat diabetes, or prevent heart attacks and strokes. That’s pushing one of the world's largest pharmaceutical companies to jump on the bandwagon.

Join Dan Koh and Ryan Huang as they look into Swiss pharmaceutical giant Roche’s $5.3 billion deal to develop Danish biotech Zealand Pharma’s obesity drug candidate, and how they stand to compete in the growing weight loss drug market.